Protocol

TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts

Rank MEDLINE abstracts for each cancer-gene-treatment topic; score against Phase 1 relevance judgements.

Overview

Rank MEDLINE abstracts for each cancer-gene-treatment topic; score against Phase 1 relevance judgements.

Consult the linked sources for architecture or protocol details. Missing evidence is not evidence of a missing capability.

9 recorded evaluations, 15 metric rows. A comparison chart has not yet been validated for these results. The table retains the individual findings and their sources.

View coverage and remaining gaps across all benchmarks

Results

Results are available, but no reviewed comparison panel is linked in this release.

All evaluations

9 evaluations · 15 results. Different protocols are not a single leaderboard.

Filter evaluations

Tested model or methodProtocolDatasetEvaluation setupMetricEvidence origin

Applied filters: All linked evaluations

Exact evaluated configurations and original reported results
Tested configuration	Protocol and dataset	Finding	Evidence and details
Configuration: TREC 2020 PM run baseline (BIT.UA)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.532 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source baseline (BIT.UA), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'infNDCG', row 1: team 'BIT.UA', run 'baseline'
Configuration: TREC 2020 PM run baseline (BIT.UA)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.552 precision-at-10 unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source baseline (BIT.UA), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'P@10', row 2: team 'BIT.UA', run 'baseline'
Configuration: TREC 2020 PM run baseline (BIT.UA)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.421 r-precision unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source baseline (BIT.UA), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'R-prec', row 2: team 'BIT.UA', run 'baseline'
Configuration: TREC 2020 PM run bm25 (ASCFDA)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.535 precision-at-10 unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source bm25 (ASCFDA), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'P@10', row 4: team 'ASCFDA', run 'bm25'
Configuration: TREC 2020 PM run CSIROmed_strRR (CSIROmed)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.53 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source CSIROmed_strRR (CSIROmed), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'infNDCG', row 2: team 'CSIROmed', run 'CSIROmed strRR'
Configuration: TREC 2020 PM run CSIROmed_strRR (CSIROmed)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.565 precision-at-10 unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source CSIROmed_strRR (CSIROmed), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'P@10', row 1: team 'CSIROmed', run 'CSIROmed strRR'
Configuration: TREC 2020 PM run CSIROmed_strRR (CSIROmed)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.436 r-precision unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source CSIROmed_strRR (CSIROmed), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'R-prec', row 1: team 'CSIROmed', run 'CSIROmed strRR'
Configuration: TREC 2020 PM run duoT5 (h2oloo)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.512 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source duoT5 (h2oloo), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'infNDCG', row 4: team 'h2oloo', run 'duoT5'
Configuration: TREC 2020 PM run monoT5 (h2oloo)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.402 r-precision unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source monoT5 (h2oloo), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'R-prec', row 5: team 'h2oloo', run 'monoT5'
Configuration: TREC 2020 PM run pozbaseline (POZNAN)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.532 precision-at-10 unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source pozbaseline (POZNAN), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'P@10', row 5: team 'POZNAN', run 'pozbaseline'
Configuration: TREC 2020 PM run r1st (PINGAN NLP)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.418 r-precision unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source r1st (PINGAN NLP), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'R-prec', row 3: team 'PINGAN NLP', run 'r1st'
Configuration: TREC 2020 PM run sibtm_run1 (BITEM)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.528 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source sibtm_run1 (BITEM), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'infNDCG', row 3: team 'BITEM', run 'sibtm run1'
Configuration: TREC 2020 PM run sibtm_run1 (BITEM)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.402 r-precision unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source sibtm_run1 (BITEM), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'R-prec', row 4: team 'BITEM', run 'sibtm run1'
Configuration: TREC 2020 PM run uog_ufmg_sb_df5 (UoGTr)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.498 ndcg unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source uog_ufmg_sb_df5 (UoGTr), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'infNDCG', row 5: team 'UoGTr', run 'uog ufmg sb df5'
Configuration: TREC 2020 PM run uog_ufmg_sb_df5 (UoGTr)	Protocol: TREC 2020 PM Phase 1: topical relevance of retrieved MEDLINE abstracts Dataset: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot	0.548 precision-at-10 unitless · higher Uncertainty: Not reported by the source Coverage: Not reported scored / Not reported eligible	Independent external evaluation · Source checked Methods, coverage and source uog_ufmg_sb_df5 (UoGTr), TREC 2020 PM Phase 1 egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance Aggregation: Not reported Overview of the TREC 2020 Precision Medicine Track; NIST TREC Browser, Precision Medicine 2020 runs page · Overview Table 5 (PDF page 9), block 'P@10', row 3: team 'UoGTr', run 'uog ufmg bg df5'

Source checking is not independent reproduction. Release 2026-10-09-ba02f2f4a36e.

Methods and evaluation design

Procedure, tasks and evaluated configurations

Recorded evaluations

Each evaluation records what was tested and under which conditions.

Baseline coverage

Reference methods help show what a model adds beyond simple controls. We track a null control and a conventional method for each protocol.

0 of 2 active baseline roles have published Rewire measurements in this release. Measurements on a selected protocol do not establish coverage of an entire suite.

No execution recipe linked to this protocol. Recipe availability does not establish a completed evaluation.

External evaluations: 9

Literature evidence is not a Rewire measurement. Executed but unpublished runs and private review status are not included.

Null control

Proposed control: requires review

Select a task-valid null control after reviewing inputs and metric

Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.

This is a suggested selection rule, not a validated method or a measured score.

Conventional reference

Proposed control: requires review

Select an upstream conventional reference after reviewing the full protocol

Protocol-specific applicability, permitted inputs, access, split, evaluator and execution requirements need review before implementation or execution.

This is a suggested selection rule, not a validated method or a measured score.

Protocol coverage CSV (gzip) · Model evaluation matrix (gzip) · Source table (gzip) · Release and checksums (gzip)

Coverage is derived from release 2026-10-09-ba02f2f4a36e. Source citations describe the original records; they do not validate an unreviewed baseline proposal. No results have been generated by this audit.

Run instructions

No runnable recipe has been reviewed for this protocol. Dataset access, model requirements, licences and compute requirements must be checked against its sources before execution.

Strengths, limitations and unresolved questions

Evidence

Source checking verifies the cited claim or transcription. It does not establish independent reproduction.

Evidence table

Inspect claims, sources and review details

Trace each statement to its source and review. A context-only reference supports the record generally; it does not verify an individual field. Source checking does not reproduce an experiment.

One row per statement and cited source. Multiple citations are not independent evaluations. Shared locators are labelled explicitly.

0 evidence rows matching the loaded filters

Claims, original sources and review scope · Release 2026-10-09-ba02f2f4a36e
Property and statement	Original source and location	Review and provenance

No evidence rows match these filters. Choose another scope or clear the search.

All evidence (JSONL) (gzip)How to read the evidence

Sources and history

Release 2026-10-09-ba02f2f4a36e · Record review: source checked

2 source records and release history

Overview of the TREC 2020 Precision Medicine Track · Original source · Proceedings of the Twenty-Ninth Text REtrieval Conference (TREC 2020), NIST Special Publication 1266; 10-page PDF
TREC 2020 Precision Medicine topics · Original source · topics2020.xml as served on 2026-10-09 (40 topics)

Download this release (gzip)

Technical metadata and extraction receipts

Stable ID: egfrnsclc-20261009-protocol-trec2020-pm-phase1-relevance

areas: dna-genomes
contexts: clinical_research
protocol: Systems return ranked MEDLINE abstracts for each topic. Judges map disease, gene and treatment matches to Definitely Relevant (gain 2), Partially Relevant (1) or Not Relevant (0). Metrics: infNDCG (sample-eval), R-precision and P@10, averaged over topics.
version: TREC 2020 PM overview sections 5.1-5.2
metric: ndcg
metric direction: higher
limitations: Pan-cancer topics; per-topic scores (including the two EGFR topics) are shown only as figures in the run appendices.; The overview prints only the best run per team for the top five teams per metric.; Topics carry no prior therapy, line or resistance context; the 2019 MEDLINE snapshot is not current evidence.; Each document was judged once; no inter-rater agreement is available (Overview section 6).; Topics name a gene, not a variant; the two EGFR topics ask about afatinib and osimertinib, and no topic asks for resistance evidence.
source locator: Overview sections 5.1-5.2 and Table 5

Related records

uses data: TREC 2020 Precision Medicine: 40 cancer-gene-treatment topics over a 2019 MEDLINE baseline snapshot
assessment: baseline (BIT.UA), TREC 2020 PM Phase 1
assessment: bm25 (ASCFDA), TREC 2020 PM Phase 1
assessment: CSIROmed_strRR (CSIROmed), TREC 2020 PM Phase 1
assessment: duoT5 (h2oloo), TREC 2020 PM Phase 1
assessment: monoT5 (h2oloo), TREC 2020 PM Phase 1
assessment: pozbaseline (POZNAN), TREC 2020 PM Phase 1
assessment: r1st (PINGAN NLP), TREC 2020 PM Phase 1
assessment: sibtm_run1 (BITEM), TREC 2020 PM Phase 1
assessment: uog_ufmg_sb_df5 (UoGTr), TREC 2020 PM Phase 1
assessed by: Review EGFR lung-cancer actionability evidence

Suggest a correction